Recent advances in antiplatelet agents

被引:40
作者
Dogné, JM
de Leval, X
Benoit, P
Delarge, J
Masereel, B
David, JL
机构
[1] Univ Liege, Dept Med Chem, B-4000 Liege, Sart Tilman, Belgium
[2] Univ Namur, Dept Pharm, B-5000 Namur, Belgium
[3] Univ Hosp Liege, CHU, Dept Thrombosis & Hemostasis, B-4000 Liege, Belgium
关键词
D O I
10.2174/0929867024606948
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Platelet aggregation plays a key role in the pathogenesis of thromboembolic diseases such as myocardial infarction, stroke, unstable angina and peripheral artery disease. Until recently, aspirin was the only antiplatelet agent available to prevent or treat these events. Over the oast several years, there has been a substantial expansion in the antiplatelet armamentarium as well as in the understanding of the clinical importance of antiplatelet therapy in limiting the complications of thrombosis. Aspirin was one of the first agents to be adopted and it remains as the standard therapy with the higher amount of available clinical information. Following aspirin, ADP receptor antagonists like ticlopidine and clopidogrel as well as phosphodiesterase inhibitors dipyridamole and cilostazol have been introduced. Glycoprotein (GP) IIb/IIIa receptor antagonists like eptifibatide, tirofiban and abciximab are the newer antiplatelet agents which act at the end of the common pathway of platelet aggregation. Although results of clinical studies with the first oral GPIIb/IIIa antagonists were disappointing, agents of the new generation might expand the potential application of GPIIb/IIIa targeted therapy. This review will highlight recent advances in the development of aspirin, phosphodiesterase inhibitors, ADP receptor antagonists and the platelet glycoprotein IIb/IIIa inhibitors. The emphasis of this paper has been placed on the chemical aspects of these agents.
引用
收藏
页码:577 / 589
页数:13
相关论文
共 113 条
  • [1] PURINOCEPTORS - ARE THERE FAMILIES OF P2X AND P2Y PURINOCEPTORS
    ABBRACCHIO, MP
    BURNSTOCK, G
    [J]. PHARMACOLOGY & THERAPEUTICS, 1994, 64 (03) : 445 - 475
  • [2] Adgey AAJ, 1998, EUR HEART J, V19, pD10
  • [3] Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation - A phase II study
    Akkerhuis, KM
    Neuhaus, KL
    Wilcox, RG
    Vahanian, A
    Boland, JL
    Hoffmann, J
    Baardman, T
    Nehmiz, G
    Roth, U
    Klootwijk, APJ
    Deckers, JW
    Simoons, ML
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 (24) : 2042 - 2055
  • [4] Albiero R, 1997, CIRCULATION, V95, P1145
  • [5] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [6] Anders R, 2001, CARDIOVASC DRUG REV, V19, P116
  • [7] [Anonymous], 1988, LANCET, V2, P349
  • [8] ANTIPLATELET TREATMENT WITH TICLOPIDINE IN UNSTABLE ANGINA - A CONTROLLED MULTICENTER CLINICAL-TRIAL
    BALSANO, F
    RIZZON, P
    VIOLI, F
    SCRUTINIO, D
    CIMMINIELLO, C
    AGUGLIA, F
    PASOTTI, C
    RUDELLI, G
    [J]. CIRCULATION, 1990, 82 (01) : 17 - 26
  • [9] Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist
    Banno, H
    Kawazura, H
    Yutaka, T
    Sakuma, N
    Kitamori, T
    Hosoya, J
    Kibayashi, K
    Yamashita, H
    Umemura, K
    Nakashima, M
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 367 (2-3) : 275 - 282
  • [10] Bazzino O, 1998, NEW ENGL J MED, V338, P1498